ID1 (F2M1J) Rabbit mAb (BSA and Azide Free) #70322
- WB
- IHC
Supporting Data
| REACTIVITY | H Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 17 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
Formulation
Storage
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant human ID1 protein.
Background
Inhibitor of DNA-binding/Differentiation (ID) proteins are a family of proteins that function to repress the activity of basic helix-loop-helix (bHLH) transcription factors. There are four known ID proteins in humans (ID1-4), all of which contain a helix-loop-helix domain but lack a basic DNA-binding domain. Heterodimerization with bHLH transcription factors, therefore, functions to sequester bHLH proteins and prevent their binding to DNA (1). ID proteins play important functional roles in development, primarily by inhibiting premature differentiation of stem/progenitor cells (1,2). ID1 plays important regulatory roles downstream of TGF-β and BMP signaling by inhibiting various transcription factors (3,4). SMAD3 is capable of binding to the ID1 promoter, causing upregulation in response to TGF-β (5). High expression of ID1 is associated with increased cancer growth and migration by inhibiting cell cycle regulators p16, p21, and p27 (6,7). ID1 as a therapeutic target is context dependent. While high expression of ID1 is generally associated with poor prognosis, drug sensitivity can vary greatly depending on tumor type (8-10).
- Yokota, Y. (2001) Oncogene 20, 8290-8.
- Hong, S.H. et al. (2011) J Cell Sci 124, 1445-52.
- Di, K. et al. (2006) Biol Cell 98, 523-33.
- Miyazono, K. and Miyazawa, K. (2002) Sci STKE 2002, pe40.
- Liang, Y.Y. et al. (2009) Cell Res 19, 140-8.
- Asirvatham, A.J. et al. (2007) Prostate 67, 1411-20.
- Alani, R.M. et al. (2001) Proc Natl Acad Sci USA 98, 7812-6.
- Castañon, E. et al. (2013) J Transl Med 11, 13.
- Li, L. et al. (2017) Oncol Lett 13, 3014-3024.
- Tan, H.Y. et al. (2020) Cancer Lett 475, 109-118.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专